InsiderSignalSign in

← Insider buys

DXCM

DexCom, Inc. · Healthcare

Insiders sold $12.3M of DexCom, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$12.3MSold, 12 mo

$32.4BMarket cap

DXCM over the last year

No insider buys filed in this year

DXCM after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Congress

Members reported 45 trades in DXCM since 2023.

Every filing

629 insider filings since 2016, newest first

Michael Jon Brown · EVP Chief Legal Compliance Off

$145K−1.7%Oct 19

Sadie Stern · EVP Chief People & Culture Off

$221K−2.0%Sep 30

Nicholas Augustinos · Director

$680K−21.6%Sep 16

Michael Jon Brown · EVP Chief Legal Compliance Off

$143K−1.7%Sep 16

Jereme M Sylvain · EVP and Chief Financal Officer

$303K−2.4%Sep 14

Sadie Stern · EVP Chief People & Culture Off

$227K−2.0%Aug 28

Kevin R Sayer · Executive Chair

$2.4M−8.1%Aug 24

Michael Jon Brown · EVP Chief Legal Compliance Off

$156K−1.6%Aug 17

Bridgette P Heller · Director

$89K−3.3%Aug 13

Mark G Foletta · Director

$331K−7.6%Aug 4

Kevin R Sayer · Executive Chair

$2.0M−7.5%Jul 21

Michael Jon Brown · EVP Chief Legal Compliance Off

$127K−1.6%Jul 16

Kevin R Sayer · Executive Chair

$1.9M−7.0%Jul 7

Michael Jon Brown · EVP Chief Legal Compliance Off

$128K−1.6%Jun 17

Mark G Foletta · Director

$297K−7.0%Jun 17

Jon Coleman · EVP and Chief Commercial Officer

$723K−9.3%Jun 5

Kevin R Sayer · Executive Chair

$1.9M−6.5%May 26

Michael Jon Brown · EVP and General Counsel

$102K−2.0%May 19

Bridgette P Heller · Director

$61K−4.0%May 14

Michael Jon Brown · EVP and General Counsel

$107K−2.0%Apr 16

Michael Jon Brown · EVP and General Counsel

$110K−1.0%Mar 18

Bridgette P Heller · Director

$69K−4.0%Feb 17

Sadie Stern · EVP and CHRO

$318K−6.0%Nov 22

Jereme M Sylvain · EVP and Chief Financal Officer

$264K−4.0%Nov 18

Bridgette P Heller · Director

$70K−4.0%Sep 17

Sadie Stern · EVP and CHRO

$29K−1.0%Sep 11

Jereme M Sylvain · EVP and Chief Financal Officer

$52K−1.0%Sep 11

Jacob Steven Leach · EVP and COO

Michael Jon Brown · EVP and General Counsel

$48K−1.0%Sep 3

Michael Jon Brown · EVP and General Counsel

$45K−1.0%Aug 1

Michael Jon Brown · EVP GC

$75K−1.0%Jun 28

Mark G Foletta · Director

$702K−9.0%Jun 20

Bridgette P Heller · Director

$114K−4.0%Jun 18

Jereme M Sylvain · EVP CFO

$86K−1.0%Jun 11

Sadie Stern · EVP CHRO

$49K−1.0%Jun 11

Jacob Steven Leach · EVP COO

Michael Jon Brown · EVP GC

$78K−1.0%May 31

Matthew Vincent Dolan · EVP Strategy, Corporate Dev

$307K−6.0%May 16

Michael Jon Brown · EVP GC

$79K−1.0%May 2

Matthew Vincent Dolan · EVP Strategy, Corporate Dev

$274K−4.0%Apr 16

Kevin R Sayer · Pres CEO, COB

$6.9M−15.0%Apr 10

Michael Jon Brown · EVP GC

$367K−4.0%Mar 29

Sadie Stern · EVP Chief HR

$579K−5.0%Mar 26

Matthew Vincent Dolan · EVP Strategy, Corp Dev

$547K−9.0%Mar 19

Teri L Lawver · EVP Chief Commercial Officer

$640K−7.0%Mar 14

Michael Jon Brown · EVP GC

$1.2M−11.0%Mar 14

Jereme M Sylvain · EVP CFO

$1.6M−12.0%Mar 14

Sadie Stern · EVP Chief HR

$2.7M−20.0%Mar 14

Kevin R Sayer · Pres CEO, COB

$10.8M−20.0%Mar 14

Jacob Steven Leach · EVP COO

$2.0M−4.0%Mar 14

About DexCom, Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.